Depletion of CD8+ T cells entirely abrogated the anti-tumor immunity of alum-CpG-HH2-NY, whereas depletion of CD4+ T cells slightly diminished the anti-tumor immunity and showed no statistical difference relative to IgG2b treatment (control) (Figure 6C). This evidence concerns the gene CD4 and neoplasm.